Prothena Corporation plc provided earnings guidance for the year 2023. The company continues to expect the full-year 2023 net cash used in operating and investing activities to be $213 million to $229 million and expects to end the year with approximately $512 million in cash, cash equivalents and restricted cash (midpoint). The estimated full-year 2023 net cash used in operating and investing activities is primarily driven by an estimated net loss of $250 million to $275 million, which includes an estimated $46 million of non-cash share-based compensation expense.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.13 USD | -2.54% | +1.54% | -41.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.85% | 1.14B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- PRTA Stock
- News Prothena Corporation plc
- Prothena Corporation plc Provides Earnings Guidance for the Year 2023